{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:19:10Z","timestamp":1788668350700,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.diabres.2024.111960","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T16:35:19Z","timestamp":1734107719000},"page":"111960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Type 2 diabetes and the minor allele of PNPLA3 consistently identify high-risk metabolic dysfunction associated steatotic liver disease"],"prefix":"10.1016","volume":"219","author":[{"given":"Zobair M.","family":"Younossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.Michael","family":"Estep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Felix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Younossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Racila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Stepanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.diabres.2024.111960_b0005","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.diabres.2024.111960_b0010","doi-asserted-by":"crossref","first-page":"e0251","DOI":"10.1097\/HC9.0000000000000251","article-title":"The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019","volume":"7","author":"Paik","year":"2023","journal-title":"Hepatol Commun"},{"issue":"6","key":"10.1016\/j.diabres.2024.111960_b0015","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.diabres.2024.111960_b0020","first-page":"e0352","article-title":"The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease","volume":"8","author":"Younossi","year":"2023","journal-title":"Hepatol Commun"},{"issue":"10","key":"10.1016\/j.diabres.2024.111960_b0025","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.diabres.2024.111960_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155642","article-title":"Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States","volume":"146","author":"Golabi","year":"2023","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.diabres.2024.111960_b0035","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.29721","article-title":"Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis","volume":"68","author":"Younossi","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.diabres.2024.111960_b0040","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabres.2024.111960_b0045","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.2337\/dci21-0020","article-title":"Preparing for the NASH epidemic: a call to action","volume":"44","author":"Kanwal","year":"2021","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.diabres.2024.111960_b0050","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cld.2023.01.022","article-title":"Noninvasive Tests Used in Risk Stratification of Patients with Nonalcoholic Fatty Liver Disease","volume":"27","author":"Henry","year":"2023","journal-title":"Clin Liver Dis"},{"issue":"6","key":"10.1016\/j.diabres.2024.111960_b0055","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/jgh.16144","article-title":"Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Noninvasive tests predict liver-related events and mortality in patients with nonalcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study","volume":"38","author":"Ishiba","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.diabres.2024.111960_b0060","article-title":"VCTE-Prognosis Study Group. Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease","volume":"21","author":"Lin","year":"2024","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.diabres.2024.111960_b0065","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1001\/jama.2024.0799","article-title":"Predicting Liver-Related Outcomes in Steatotic Liver Disease","volume":"331","author":"Younossi","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2024.111960_b0070","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2024.111960_b0075","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diabres.2024.111960_b0080","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabres.2024.111960_b0085","unstructured":"European Association for the Study of the Liver; European Association for the Study of Diabetes; European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024 Sep;81(3):492-542."},{"key":"10.1016\/j.diabres.2024.111960_b0090","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Zelber-Sagi S, Kuglemas C, Lazarus JV, Paik A, de Avila L, Gerber L, Paik JM. Association of food insecurity with MASLD prevalence and liver-related mortality. J Hepatol. 2024 Aug 28:S0168-8278(24)02489-9. doi:10.1016\/j.jhep.2024.08.011. Epub ahead of print. PMID: 39208992.","DOI":"10.1016\/j.jhep.2024.08.011"},{"issue":"6","key":"10.1016\/j.diabres.2024.111960_b0095","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/apt.17308","article-title":"Vigorous physical activity provides protection against all-cause deaths among adults patients with nonalcoholic fatty liver disease (NAFLD)","volume":"57","author":"Henry","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.diabres.2024.111960_b0100","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3350\/cmh.2023.0485","article-title":"Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"30","author":"Le","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.diabres.2024.111960_b0105","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.diabres.2024.111960_b0110","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.diabres.2024.111960_b0115","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1053\/j.gastro.2023.01.040","article-title":"PNPLA3 Genotype and Diabetes Identify Patients With Nonalcoholic Fatty Liver Disease at High Risk of Incident Cirrhosis","volume":"164","author":"Chen","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabres.2024.111960_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101143","article-title":"Metabolic drivers of non-alcoholic fatty liver disease","volume":"50","author":"Bence","year":"2021","journal-title":"Mol Metab"},{"issue":"12","key":"10.1016\/j.diabres.2024.111960_b0125","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.diabres.2024.111960_b0130","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.diabres.2024.111960_b0135","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.diabres.2024.111960_b0140","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.diabres.2024.111960_b0145","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/liv.15845","article-title":"Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus","volume":"44","author":"Lavrado","year":"2024","journal-title":"Liver Int"},{"issue":"24","key":"10.1016\/j.diabres.2024.111960_b0150","first-page":"00690","article-title":"Genetics of MASLD: The State of Art Update","volume":"S1542\u20133565","author":"Sookoian","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.diabres.2024.111960_b0155","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/j.gastro.2023.06.013","article-title":"AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review","volume":"165","author":"Wattacheril","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabres.2024.111960_b0160","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Diabetologia. 2024 Nov;67(11):2608.","DOI":"10.1007\/s00125-024-06258-6"},{"issue":"7","key":"10.1016\/j.diabres.2024.111960_b0165","article-title":"Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants","volume":"6","author":"Bril","year":"2024","journal-title":"JHEP Rep"},{"issue":"5","key":"10.1016\/j.diabres.2024.111960_b0170","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cgh.2023.12.009","article-title":"Age, BMI, and Type 2 Diabetes Modify the Relationship Between PNPLA3 and Advanced Fibrosis in Children and Adults With NAFLD","volume":"22","author":"Jarasvaraparn","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.diabres.2024.111960_b0175","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2741\/4892","article-title":"Current treatment paradigms and emerging therapies for NAFLD\/NASH","volume":"26","author":"Raza","year":"2021","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"5","key":"10.1016\/j.diabres.2024.111960_b0180","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ueg2.12556","article-title":"Are we ready for genetic testing in metabolic dysfunction-associated steatotic liver disease?","volume":"12","author":"Tulone","year":"2024","journal-title":"United European Gastroenterol J"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822724008702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822724008702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T01:56:08Z","timestamp":1740102968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822724008702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":36,"alternative-id":["S0168822724008702"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2024.111960","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type 2 diabetes and the minor allele of PNPLA3 consistently identify high-risk metabolic dysfunction associated steatotic liver disease","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2024.111960","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111960"}}